Athersys, Inc. (ATHX)

NASDAQ: ATHX · IEX Real-Time Price · USD
0.255
-0.020 (-7.35%)
At close: Jun 24, 2022 4:00 PM
0.254
-0.001 (-0.314%)
After-hours: Jun 24, 2022 6:12 PM EDT
-7.35%
Market Cap 65.76M
Revenue (ttm) 8.43M
Net Income (ttm) -82.70M
Shares Out 258.07M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE 0.86
Dividend n/a
Ex-Dividend Date n/a
Volume 25,645,915
Open 0.265
Previous Close 0.275
Day's Range 0.253 - 0.274
52-Week Range 0.180 - 1.810
Beta -1.26
Analysts Sell
Price Target 1.14 (+347.4%)
Earnings Date Aug 8, 2022

About ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ... [Read more...]

Industry Biotechnology
Founded 1995
CEO Gil Van Bokkelen
Employees 104
Stock Exchange NASDAQ
Ticker Symbol ATHX
Full Company Profile

Financial Performance

In 2021, Athersys's revenue was $5.51 million, an increase of 282.92% compared to the previous year's $1.44 million. Losses were -$86.96 million, 10.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ATHX stock is "Sell." The 12-month stock price forecast is 1.14, which is an increase of 347.41% from the latest price.

Price Target
$1.14
(347.41% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX--In connection with the Company's cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from 10 to 5 members.

Athersys Postpones Annual Meeting of Stockholders

CLEVELAND--(BUSINESS WIRE)---- $ATHX--The Athersys Annual Meeting of Stockholders is rescheduled to Thursday, July 28, 2022, 8:30 a.m. ET

Athersys Hosting KOL Panel Event to Discuss TREASURE Data

CLEVELAND--(BUSINESS WIRE)---- $ATHX #investorconference--Athersys will moderate a KOL panel of neurology experts to share their perspectives on the topline data from the TREASURE study.

Top Penny Stocks To Buy For Under $1? 3 To Watch This Week

Stocks Under $1 To Watch This Week. The post Top Penny Stocks To Buy For Under $1?

Other symbols: LVOSESN

Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs

CLEVELAND--(BUSINESS WIRE)---- $ATHX #investorconference--Athersys announces a corporate restructuring plan to reduce costs and prioritize its lead clinical programs for MultiStem cell therapy.

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

Athersys-Partnered Japanese Ischemic Stroke Study Disappoints, Shares Plunge

Athersys Inc's (NASDAQ: ATHX) partner, Healios K.K. has reported topline results for its Japan ischemic stroke study, TREASURE.

Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke ...

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Topline data from the largest cell therapy clinical trial ever run in Japan, evaluating Athersys' MultiStem (invimestrocel) for ischemic stroke.

Penny Stocks To Buy Now? Top Short Squeeze Stocks To Watch

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy Now?

Other symbols: BBIGCSSEMULNRDBX

Athersys to Participate in the H.C. Wainwright Global Investment Conference

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being...

7 Biotech Stocks With Key Catalysts for May

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorP...

Are These Hot Penny Stocks on Your Watchlist Right Now?

Check these three penny stocks out for your watchlist The post Are These Hot Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: GTEIAG

Athersys Reports First Quarter 2022 Results

CLEVELAND--(BUSINESS WIRE)---- $ATHX #MultiStem--Athersys will host a conference call after its partner Healios announces the topline data for its TREASURE study evaluating MultiStem for stroke.

Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference

CLEVELAND--(BUSINESS WIRE)---- $ATHX #investorconference--Athersys executives will present in person and participate in one-on-one meetings with institutional investors.

Athersys to Announce First Quarter Financial Results on May 6

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #earningsdate--Athersys Q1 Conference Call to be Held Following Announcement of Phase 2/3 TREASURE Data in May.

Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now

Short squeeze penny stocks to watch. The post Penny Stocks To Buy?

Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

CLEVELAND--(BUSINESS WIRE)---- $ATHX--Topline Phase 2/3 TREASURE data evaluating MultiStem cell therapy for the treatment of ischemic stroke patients in Japan is expected in May.

Athersys to Participate in Two Upcoming Investor Conferences

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will present a corporate overview at the Locust Walk Stem Cell Conference, April 11, and at the Needham Healthcare Conference, April 13.

Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)---- $ATHX #earnings--Dan Camardo, newly appointed Chief Executive Officer of Athersys, shares his initial perspective on the path to commercial success for the Company.

Is Athersys, Inc. (ATHX) Stock Outpacing Its Medical Peers This Year?

Here is how Athersys, Inc. (ATHX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). Stock Option Award Offered to Daniel Camardo, new Chief Executive Officer.

Athersys to Host Year-End 2021 Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys to Host Year-End 2021 Financial Results Call; New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022

5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit

Penny stocks under $1 The post 5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: EBONGTESNDLXCUR

Athersys to Host a Virtual Presentation on Its MultiStem® Programs

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ards--Athersys event will provide an understanding of the expected program milestones and why the Company is well-positioned to deliver on its mission.

Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--New Athersys CEO Dan Camardo brings extensive market launch experience to lead the Company forward on its path to commercialization.